VAIA
ACAD icon

Virtus Alternative Investment Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-137
Closed -$7K – 3
2020
Q4 		$7K Sell
137
-133
-49% -$6.6K 0.1% 102
2020
Q3 		$11K Buy
+270
New +$11.7K 0.2% 85

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Virtus Alternative Investment Advisers's ACAD Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 137 shares — an estimated $7K sold.

Virtus Alternative Investment Advisers first reported a position in ACAD in Q3 2020 and held it in 2 quarters. The position peaked at $11K in Q3 2020. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 137 Acadia Pharmaceuticals shares in Q1 2021, an estimated $7K.
  • Virtus Alternative Investment Advisers first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Virtus Alternative Investment Advisers's Acadia Pharmaceuticals position peaked at $11K in Q3 2020.
  • 272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.